Glucotrack (GCTK) Stock News

Glucotrack (NASDAQ:GCTK) announced its participation in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting from August 8-11, 2025 in Phoenix, AZ. The company will showcase its innovative Continuous Blood Glucose Monitor (CBGM) at Booth #1724 and present a scientific poster on endocrinologist perspectives regarding implantable monitoring technology.

Glucotrack's CBGM technology represents a significant advancement in diabetes management, offering a fully implantable solution that lasts up to three years. Unlike traditional CGMs that measure glucose in interstitial fluid through skin-worn devices, this system measures glucose directly from blood without requiring any external wearables. The company is preparing to begin its long-term early feasibility study following successful initial clinical validation.

Glucotrack (Nasdaq: GCTK) has announced the successful repurchase of over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025. The company repurchased approximately 49,700 Series A Warrants using existing cash, with about 4,300 warrants remaining outstanding. The warrants were originally issued as part of a $10M Public Offering in November 2024.

The repurchase is part of Glucotrack's capital formation strategy and demonstrates confidence in its development of a long-term implantable continuous blood glucose monitoring system for diabetes patients. The company's Series B Warrants were previously converted to common stock, as reported in Q1 2025.

Glucotrack (NASDAQ:GCTK) has announced positive final results from its first-in-human clinical study for its innovative Continuous Blood Glucose Monitor (CBGM) at the American Diabetes Association's 85th Scientific Sessions. The study demonstrated excellent accuracy with a MARD of 7.7% across 122 matched pairs and a 99% data capture rate, with no serious adverse events.

The implantable CBGM technology measures glucose directly from blood rather than interstitial fluid, eliminating typical lag time associated with traditional monitors. The study, conducted in Brazil from December 2024 to January 2025, included ten Type 1 or Type 2 diabetes patients. Analysis showed 92% of measurements in the green zone of the Diabetes Technology Society Error Grid, indicating high clinical accuracy.

The company plans to initiate a long-term early feasibility study in Q3 2025. The CBGM system is designed for a three-year sensor life with no on-body wearable component and minimal calibration requirements.

Glucotrack (NASDAQ: GCTK) announced a 1-for-60 reverse stock split effective June 16, 2025, aimed at maintaining its NASDAQ listing compliance. The company's outstanding common stock will be reduced from 32,541,327 to approximately 542,356 shares, with stockholders' ownership percentages remaining unchanged except for fractional shares being rounded up. The split was approved by shareholders on May 22, 2025, authorizing management to implement a ratio up to 1-for-100. This strategic move is primarily intended to meet NASDAQ's $1.00 minimum bid price requirement and attract institutional life science investors. The company must maintain compliance with NASDAQ listing rules through September 29, 2025, to avoid potential delisting.

Glucotrack (NASDAQ: GCTK) announced its participation in the American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23, 2025, where it will present safety and performance data from its first-in-human trial of an implantable continuous blood glucose monitoring (CBGM) system. The company's Chief Scientific Officer, Mark Tapsak, will deliver a presentation on the future of continuous glucose monitoring at the Innovation Hub. Unlike traditional CGM devices that measure glucose in interstitial fluid through skin-worn sensors, Glucotrack's innovative CBGM system is designed to be implanted in the body, directly measuring blood glucose levels without requiring external wearables, and lasting up to three years. The technology aims to minimize daily disruptions for diabetes patients while providing real-time, accurate readings.

Glucotrack (NASDAQ: GCTK) has announced the election of Victoria E. Carr-Brendel, PhD to its Board of Directors, effective May 22, 2025. Dr. Carr-Brendel brings extensive experience in medical devices and implantable technologies, currently serving on Vicarious Surgical's board and previously leading Cochlear Implants at Sonova Group. She has held leadership positions at JenaValve Technology and Boston Scientific, with a career spanning roles at Dexcom and Baxter Healthcare.

Glucotrack is developing a long-term implantable Continuous Blood Glucose Monitoring (CBGM) system designed to function for up to three years without any wearable components. The system measures glucose directly from blood, aiming to provide real-time readings without the lag time associated with traditional interstitial fluid measurements. The device is currently in investigational status under U.S. law.

Glucotrack Inc. (NASDAQ: GCTK) has announced the formation of a Patient Advisory Board (PAB) to enhance the development of its long-term implantable Continuous Blood Glucose Monitor (CBGM). Following their successful first-in-human clinical study, the PAB will include individuals with direct diabetes experience to provide insights on product development and commercialization strategies.

The company's CBGM technology is designed as a long-term implantable system with no wearable component, offering up to three years of continuous monitoring. Unlike traditional monitors that measure glucose from interstitial fluid, Glucotrack's device measures directly from blood, potentially eliminating typical lag times in readings. The inaugural PAB meeting was held on May 3, 2025, with regular meetings planned to gather ongoing patient feedback.

Glucotrack (NASDAQ: GCTK) reported its Q1 2025 financial results and corporate updates. The company is advancing its fully implantable continuous blood glucose monitor (CBGM) system, with plans to begin patient implants in Australia in Q3 2025 and expected FDA IDE approval in Q4 2025. Key developments include ethical approval in Australia for clinical studies, participation in FORGETDIABETES European research initiative, and collaboration with OneTwo Analytics for AI-driven data analysis. Financial results showed R&D expenses of $1.9M (down from $2.1M in Q1 2024), while MG&A expenses increased to $1.6M (from $0.8M). Net loss widened to $6.8M (from $2.9M), primarily due to derivative liabilities changes. The company's cash position strengthened to $9.1M as of March 31, 2025, which is expected to fund its 2025 operating plan including clinical trials.

Glucotrack (NASDAQ: GCTK) has received ethical approval from St. Vincent's Hospital Melbourne HREC for a long-term clinical study of its continuous blood glucose monitor (CBGM) for diabetes patients. The study will enroll up to 30 participants with type 1 and type 2 diabetes mellitus, initially running for 1 year with potential extension to 3 years.

The study will be led by Professor David O'Neal and Associate Professor Neale Cohen, with first patient implants expected by July 2025. Glucotrack's CBGM is a long-term implantable system designed for up to three years of continuous monitoring, featuring no wearable components and direct blood glucose measurement, unlike traditional systems that measure from interstitial fluid.

The approval follows Glucotrack's successful first-in-human study, marking a significant advancement in their clinical program.